Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10391870 | 0.89 | ALDH1A1 (0.68) | ALDH1A1CYP3A4KMT2ATSHRPOLB | |
| SCHEMBL9007847 | 0.89 | ALDH1A1 (0.68) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL10469561 | 0.89 | ALDH1A1 (0.51) | ALDH1A1CYP3A4KMT2AHSP90AA1MAPT | |
| SCHEMBL10631729 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL10366604 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL10422763 | 0.88 | CYP3A4 (0.55) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL10408719 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL10638069 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL9770404 | 0.88 | ALDH1A1 (0.57) | ALDH1A1CYP3A4KMT2ATSHRHSP90AA1 | |
| SCHEMBL950886 | 0.88 | ALDH1A1 (0.50) | ALDH1A1CYP3A4KMT2AHSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193369-A1 | Antifungal compounds and uses therefor | PROTEZ PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | claimed |
| WO-2002036203-A2 | AZOLE CONTAINING COMPOSITIONS WITH ENHANCED ANTIFUNGAL ACTIVITY | INFLUX, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| EP-0538442-B1 | METHOD FOR IMPROVING THE THERAPEUTIC EFFICIENCY OF LIPOSOLUBLE ANTIFUNGAL AGENTS FROM THE IMIDAZOLE FAMILY, AND COMPOSITION FOR IMPLEMENTING SAME | OREAL (FR) | 1995-06-21 | — | — | EP | claimed |
| EP-0538442-A1 | METHOD FOR IMPROVING THE THERAPEUTIC EFFICIENCY OF LIPOSOLUBLE ANTIFUNGAL AGENTS FROM THE IMIDAZOLE FAMILY, AND COMPOSITION FOR IMPLEMENTING SAME. | OREAL (FR) | 1993-04-28 | — | — | EP | claimed |
| WO-1992019225-A1 | METHOD FOR IMPROVING THE THERAPEUTIC EFFICIENCY OF LIPOSOLUBLE ANTIFUNGAL AGENTS FROM THE IMIDAZOLE FAMILY, AND COMPOSITION FOR IMPLEMENTING SAME | L'OREAL (FR) | 1992-11-12 | — | — | WO | claimed |
| EP-0315861-B1 | ANTIMYCOTIC COMPOSITIONS OF A NIKKOMYCIN COMPOUND AND AN ANTIMYCOTIC AZOLE | BAYER AG (DE) | 1992-01-29 | — | — | EP | claimed |
| EP-0310122-B1 | ANTIFUNGAL COMPOSITION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1991-07-24 | — | — | EP | claimed |
| EP-0181529-B1 | Optically active 2-(4-chloro-phenoxymethly)-3, 3-dimethyl-1-(1,2,4-triazol-1-yl)-2-butanol, process for its preparation as well as its use as an antimycotic agent. | BAYER AG (DE) | 1991-03-27 | — | — | EP | claimed |
| EP-0224077-B1 | PLANT GROWTH REGULATING AGENT | BAYER AG (DE) | 1990-08-08 | — | — | EP | claimed |
| US-4897107-A | PLANT GROWTH REGULATORS; FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-01-30 | — | — | US | claimed |
| EP-0310122-A1 | Antifungal composition | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | claimed |
| US-4783538-A | PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-08 | — | — | US | claimed |
| EP-0224077-A1 | Plant growth regulating agent | BAYER AG (DE) | 1987-06-03 | — | — | EP | claimed |
| EP-0181529-A2 | Optically active 2-(4-chloro-phenoxymethly)-3, 3-dimethyl-1-(1,2,4-triazol-1-yl)-2-butanol, process for its preparation as well as its use as an antimycotic agent. | BAYER AG (DE) | 1986-05-21 | — | — | EP | claimed |
| US-4564622-A | Triazole derivative as an antiviral agent | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-14 | — | — | US | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| US-20230293492-A1 | METHODS AND COMPOSITIONS FOR TREATING CUTANEOUS FUNGAL INFECTIONS | PROPEDIX, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-0057357-A2 | Plant growth stunting agent | BAYER AG (DE) | 1982-08-11 | — | — | EP | disclosed |
| EP-0043419-A1 | Antimycotic composition | BAYER AG (DE) | 1982-01-13 | — | — | EP | disclosed |
| EP-0040345-A1 | 1-Hydroxyethyl-azole derivatives, process for their preparation and their use in the regulation of plant growth and as fungicides | BAYER AG (DE) | 1981-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193369-A1 | Antifungal compounds and uses therefor | CYP51A1, ERG28, TPP1 | ALDH1A1 1449/4885CYP3A4 18/4885KMT2A 2672/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | ALDH1A1 2279/4885CYP3A4 171/4885KMT2A 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.